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Digoxin, HIF-1, and cancer
In a recent issue of PNAS, Zhang et al. (1) find that digoxin
inhibits HIF-1 (a transcription factor highly involved in cancer
development) and suggest that this effect might be observed
in patients taking this drug. They also report that digoxin
blocks tumor growth in mice (1). These data suggest that
digoxin has anticancer potential.
The authors observe that digoxin inhibits HIF-1 at 100 nM
and discuss that the therapeutic plasma concentrations of
digoxin in cardiac patients are 10–30 nM (1). Extensive
clinical use of digoxin has shown that the therapeutic plasma
concentrations of this drug are 1.6  1.0 nM and that higher
concentrations induce toxicity because of its narrow therapeu-
tic window (2). These data do not support the idea of HIF-1
being inhibited in patients treated with digoxin.
It has been known for some time that mouse cells are 100
times more resistant than human cells to the effects of
digoxin and other cardiac glycosides (3). This means that the
anticancer effects induced by digoxin in mice harboring hu-
man malignant cells (1) are probably due to interspecies dif-
ferences in sensitivity and not to selective inhibition of tumor
cells. Accordingly, unlike digitoxin, evidence suggests that
digoxin does not inhibit the growth of cancer cells selectively
(4, 5).
In brief, Zhang et al. (1) demonstrate that cardiac glyco-
sides are a new class of HIF-1 inhibitors. However, it seems
unlikely that digoxin inhibits HIF-1 at therapeutic concentra-
tions or that the anticancer effects that they observed in mice
are relevant in humans.
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